U.S. court invalidates Teva’s Copaxone patent

The U.S. Court of Appeals has again ruled that Teva Pharmaceuticals Industries Ltd.’s patent for its top-selling multiple sclerosis treatment Copaxone is invalid. A Teva spokeswoman said that the company is More...